Recently, BVI Medical, a global leading ophthalmic surgical equipment companyBVI Medical Announce that the company has completed its cooperation with asset management company TPG.Raised$1 billion(Strategic capital of approximately 7.245 billion RMB), this financing may be in recent yearsThe Largest Financing in the Ophthalmic Instruments Field。
BVI Medical Completes This Round of FinancingRepaid existing debt, andIncrease equity from TPG and new investors,Optimized the company's capital structure, reduce financial leverage, and be able to invest more flexibly in R&D, production expansion, and market development, assisting the company.Accelerate product development and expand its global business footprint。
TPG manages total assets exceeding $246 billion. This investment in BVI Medical not only demonstrates its confidence in the ophthalmic healthcare market but also marksBVI Medical Takes a Significant Step in Challenging the Market Position of Ophthalmic Giants like Alcon and Zeiss。
BVI's business covers multiple细分 markets such as ophthalmic surgical instruments, intraocular lenses, and minimally invasive surgical equipment, spanning over 90 countries worldwide.The core products include the intraocular lens series., especially the FINEVISION® seriesAnd SERENITY® Series。In July 2023, BVI Medical opened a new intraocular lens (IOL) manufacturing plant in Liège, Belgium. The new facility significantly enhances IOL production and R&D capabilities, unlocking new growth opportunities while maintaining the company’s sustainability and quality standards.From the perspective of the global intraocular lens competitive landscape, Alcon has gained a leading market position with its strong portfolio of intraocular lens products.The four leading global intraocular lens companies, Alcon, Johnson & Johnson, Bausch + Lomb, and Carl Zeiss, together account for over 60% of the global market share.; at the same time, advanced technologies such as bifocal, trifocal, and extended depth-of-focus intraocular lenses are also mainly controlled by these four companies.This financing is an important turning point for BVI's development,Not only does it provide strong financial support for its accelerated global expansion, but it also lays a solid foundation for challenging the market position of seasoned suppliers in the ophthalmic medical device field.By promoting the widespread adoption of breakthrough technologies among surgeons worldwide, it is expected to reshape the future of ophthalmic surgery and transform the competitive landscape of the industry.# Intraocular Lens Pipeline
- Trifocal Intraocular Lens
PhysIOL, a renowned intraocular lens manufacturer under BVI, offers a range of products including hydrophobic and hydrophilic blue light-filtering intraocular lenses such as FineVision Trifocal HP, FineVision Trifocal, FineVision, and Trifocal Toric.Finevision trifocal intraocular lens, AT Lisa (Zeiss), and Panoptix (Alcon) are the three most common types of trifocal intraocular lenses used clinically.。FineVision hasHydrophobic Materials and Hydrophilic MaterialsTwo designs, with their hydrophobic products available in both traditional material and non-glare material versions.FineVisionHP is the third-generation hydrophilic trifocal IOL, utilizing the patented CoPODize™ technology, combining convolution (reducing halos) with deconvolution (optimizing distance vision) design,Provide full-range vision correction。- Single-Focus Intraocular Lens
PODEYE Toric Monofocal Intraocular LensDesigned for the Japanese market, the second-generation product will be launched in 2024, emphasizing precise refractive correction.This is a product based onNo ShimmerMaterials for intraocular lenses, using a new type of hydrophobic acrylic material,Featuring a dual C-ring antenna design, combined with Ridgetech technology and a rear-tilted antenna, ensuring the stability of the lens inside the eye.Ridgetech technology optimizes the edge design and surface characteristics of the lens.Reduce postoperative complications and improve visual quality; The design of the posteriorly tilted haptics allows the lens to better conform to the posterior wall of the capsular bag after implantation in the eye.Reduce the possibility of rotation and displacement。ISOPURE IOL isA fully refractive aspherical single-focus intraocular lens designed specifically for cataract patients.Adopting a hydrophobic, non-diffractive aspheric design,Providing functional intermediate vision through equifocal technology while maintaining high-quality visual outcomes。In clinical applications, a high proportion of patients achieved uncorrected binocular intermediate vision of 20/25 or better at both 80 cm and 66 cm. The visual depth curve of this IOL demonstrates good far and intermediate vision performance, with a depth of field value of 1.50D, and shows fewer optical phenomena compared to other EDOF IOLs.Patients express high satisfaction with the ISOPURE IOL, particularly in terms of reducing dependence on glasses and minimizing optical phenomena.。SERENITY and SERENITY Toric IOL are the second-generation products in the company's ISOPURE series, first launched in 2019. These non-diffractive, aspheric IOLs utilize patented ISOFOCAL optical technology.Provides distance and intermediate vision, with distance vision comparable to traditional monofocal IOLs, and an intermediate vision range of up to 66 centimeters.。SERENITY Toric IOL is specifically designed for patients with astigmatism, utilizing BVI's exclusive dual C-ring POD platform, which allows for clockwise or counterclockwise rotation to precisely align the cylindrical axis, ensuring stable positioning of the lens within the capsule. These IOLs are expected to be launched in 2025.BVI Medical Believes SERENITY Series May Become the New Standard for Monofocal Surgery。In addition, BVI Medical also providesRetinal Surgery Consumables, such as the VitreQ® product line, including the VitreQ Squeezer pencil-type injection device, which precisely controls dye and perfluorocarbon liquid injections, suitable for complex retinal detachment repairs.Retractable Tissue Manipulator: The silicone tip design reduces retinal trauma and is used for delicate operations such as macular hole surgery.Disposable lenses and catheters：PMMA material high refractive index lenses improve imaging quality, and silicone catheters reduce surgical risks.# Expand Business Territory
BVI Medical is also very active in the capital market, continuously improving its product lines and sales channels through a series of strategic acquisitions, making its ophthalmic solutions more competitive.Both M&A deals in 2023 and 2024 made it to the top ten ophthalmology M&A lists of the respective years.。In April 2017, the acquisition of the UKMalosa Ltd., enhanced the combination of disposable surgical instruments, and perfected the supply of cataract and retina surgery consumables.In July 2017, the acquisition of the NetherlandsVitreq, expanded the vitreoretinal surgery product line, such as silicone oil injectors and retinal lenses, strengthening the layout in the European market.In December 2018, the acquisition of BelgiumPhysIOL S.A., gained advanced intraocular lens (IOL) technology, driving innovation in the field of refractive correction.In 2019, acquired FranceArcadophtha SARL, acquiring the silicone oil and gas product line for retinal surgery, forming a synergistic effect with Vitreq, and enhancing vertical integration capabilities.In 2020, the acquisitionBenz and its custom contact lens subsidiary SpecialEyesBenz's innovative high-performance material portfolio in the manufacture of intraocular lenses and contact lenses complements BVI Medical's intraocular lens portfolio under the PhysIOL brand.In 2023, AcquisitionMedical Mix，Medical Mix, founded in 1982, is one of the largest suppliers of ophthalmic surgical products in Spain and Portugal. Since 2008, Medical Mix has been a long-term distributor of BVI Medical's intraocular lens products, began distributing its consumables in 2012, and started distributing its equipment in 2019. This acquisition solidifies the long-standing partnership between the two parties, strengthening BVI Medical's position.Directly enter the Iberian market,Perfect the Western European direct sales network, covering all major countries in Europe.。In 2024, AcquisitionSurgical Specialties Corporation Ophthalmology Division, this acquisition added high-precision micro-scissors and suture materials and other disposable surgical devices, injecting new vitality into BVI Medical's product line. As a global leading supplier of ophthalmic surgical equipment, BVI Medical has taken this strategic move,Strengthened its leading position in the ophthalmic surgical consumables market, and provide doctors with higher-quality surgical tools.These acquisition events indicate that BVI MedicalBuild a full ophthalmic solution through technology complementation, regional penetration, and product line enhancement., consolidating its leadership position in the industry.
# About BVI Medical
BVI Medical is a globally leading ophthalmic surgical device company, focusing on the development, manufacturing, and sales of innovative medical devices for cataract, retina, glaucoma, and refractive surgeries.Under its umbrella are several well-known brands, including Beaver.®(Surgical blade), Visitec®(Perfusion Tube), Malosa®(Disposable surgical instruments), Vitreq®(Vitreoretinal Surgery Products) and PhysIOL®(High-end intraocular lens).By continuously expanding its global business footprint, the company has become a key player in the field of ophthalmic surgery, with its products and services improving the quality of life for millions of patients worldwide.
